131I-metaiodobenzylguanidine (131I-MIBG) therapy for residual neuroblastoma : a mono-institutional experience with 43 patients

摘要: Incomplete response to therapy may compromise the outcome of children with advanced neuroblastoma. In an attempt improve tumour we incorporated 131I-metaiodobenzylguanidine (131I-MIBG) in treatment regimens selected stage 3 and 4 patients. Between 1986 1997, 43 neuroblastoma patients older than 1 year at diagnosis, 13 (group A) 30 disease B) who had completed first-line protocol without achieving complete entered this study. 131I-MIBG dose/course ranged from 2.5 5.5 Gbq (median, 3.7). The number courses 5 (median 3) depending on toxicity. most common acute side-effect was thrombocytopenia. Later side-effects included severe interstitial pneumonia one patient, myeloid leukaemia two, reduced thyroid reserve 21. Complete documented partial 12 (two 3, 10 4), mixed or no 25 (ten 15 4) progression five (one four Twenty-four (12/13 12/30 are alive 22–153 months 59) diagnosis. increase cure rate residual after therapy. A larger should be treated confirm these results but logistic problems hamper prospective coordinated studies. Long-term toxicity can severe. © 1999 Cancer Research Campaign